- Menu
- 1. Traitement de l’ostéoporose: Faux concepts et vérités scientifiques
- 2. La Vitamin D (+Ca) suffit…
- 3. Fracture liaison service
- 4. RCT: 800 UI/j
- 5. Fracture risk reduction
- 6. La Vitamin D (+Ca) çA SERT A RIEN…
- 7. Jama 2018
- 8. Effect of monthly high dose vitamine D
- 9. Effects of combined vitamin D an calcium supplementation
- 10. Les antiresorbeurs fragilisent l’os (par manque de remodellage)
- 11. Atypical Femoral Fracture
- 12. DMAB – ZOL H2H trial Serum Concentrations of Bone Turnover Markers Over Time
- 13. RESULTS Percentage Change from Baseline in BMD at Month 12
- 14. Effects of Denosumab Treatment
- 15. Skeletal Benefit/Risk Ratio of Denosumab: a virtual tween analysis over 10 yrs of continuous therapy
- 16. Un gain de dmo sous traitement ne signifie pas une reduction du risque de fractures
- 17. BMD gains on therapy correlate with fracture risk reduction
- 18. BMD gains on therapy correlate with fracture risk reduction
- 19. Table 5
- 20. LE TERIPARATIDE EST UN TRAITEMENT DE TROISIEME INTENTION (ECHEC DES BPs)
- 21. EFFECTS OF 24 MONTHS TREATMENT OF TERIPARATIDE COMPARED WITH RISEDRONATE ON NEW FRACTURES IN POSTMENOPAUSAL WOMEN
- 22. EFFECTS OF 24 MONTHS TREATMENT OF TERIPARATIDE COMPARED WITH RISEDRONATE ON NEW FRACTURES IN POSTMENOPAUSAL WOMEN
- 23. Tout traitement doit etre stoppe après 3-5 ans
- 24. Risque de fracture à l’arrêt de l’ALN (5 ans) (PBO group – Etude FLEX – 5 ans de suivi)
- 25. Managing osteoporose in patients on long term biphosphonate treatment
- 26. Goal-directed treatment for osteoporosis
- 27. Relationship between total hip T-score and nonvertebral fracture
- 28. On- vs Off-Treatment Vertebral Fracture Rate (per 100 Subject-Years)
- 29. Zol after Dmab (n=97)
- 30. When to stop? When to switch?
- 31. Conclusions